2A Pharma AB

Swedish/Danish Biotech Company 2A Pharma Raises SEK 27 Million and Signs Exclusive Worldwide License Agreement

Press Release   •   Jan 16, 2017 07:01 CET

New Swedish/Danish biotech company 2A Pharma AB has closed its first financing round and has been granted an exclusive, worldwide license from Medigene AG (FSE: MDG1) for its adeno-associated virus like particles (AAVLPs) technology.

Malmö, Sweden, 16 January 2016. 2A Pharma AB, based in Malmö, Sweden with research facilities in Aalborg, Denmark, aims to develop novel, cost effective vaccines and therapeutics based on Medigene AG’s AAVLP technology which was exclusively in-licensed by 2A Pharma AB in December 2016. The company’s first financing round of SEK 27 million, closed in December 2016, provides sufficient funding to complete phase I clinical trials of the lead drug candidate.

Prof.Dr. Søren Nielsen, CEO of 2A Pharma AB: “We are extremely pleased with the support we have received from our investors and the progress the team has achieved in a very short period. We believe we have tremendous opportunities to develop the company and its products, both internally and with partners. Our initial focus is to maintain an aggressive schedule for our first project to enable us to start clinical trials in 2018. This follows our strategy at Aalborg University to take science out where it makes a difference.”

Dr. John Nieland, COO of 2A Pharma AB and co-inventor of the AAVLP technology, adds: “The AAVLP platform is versatile and can be applied to a wide range of vaccines and therapeutics. While we currently focus on our lead drug candidate, a HPV vaccine which in laboratory tests has shown potential to be a very significant improvement over existing approved products, we have three other vaccines ready for clinical development and a significant pipeline of development opportunities.”

About AAVLP: AAVLPs offer the potential to develop vaccines and therapeutics against various indications, including cancer and infectious diseases. The adeno-associated virus is non-pathogenic, and the virus protein shell, the capsid, is well-suited to produce virus-like particles, as a basis for novel vaccines. AAVLPs have previously been developed as B-cell vaccines. Peptides inserted in the capsid can induce a humoral immune response (B-cell induction and antibody production). The first preclinical tests with AAVLPs were conducted by academic partners of Medigene AG.

2A Pharma AB was founded in December 2016 in Malmö, Sweden, with Prof.Dr. Søren Nielsen as CEO, Preben Bruun-Nyzell as CFO and Dr. John Nieland as COO, as a start-up biotech company with the aim to develop novel vaccine products. Strong private investors participated in the company’s first financing round. Jensen Corporate Finance, Malmö, www.jensencf.com, advised 2A Pharma.

For more information, please visit www.2apharma.com

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit www.medigene.com

Contact 2A Pharma AB

Prof. Dr. Søren Nielsen, CEO

Tel: +45 2539 4137

Email: sn@2apharma.com

2A Pharma AB was founded in December 2016 in Malmö, Sweden, with Prof.Dr. Søren Nielsen as CEO, Preben Bruun-Nyzell as CFO and Dr. John Nieland as COO, as a start-up biotech company with the aim to develop novel vaccine products. Strong private investors participated in the company’s first financing round.